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PDE type 5 inhibitors (PDE5Is), such as sildenafil, tadalafil and vardenafil, are a class
of drugs used to prolong the physiological effects of NO/cGMP signalling in tissues
through the inhibition of cGMP degradation. Although these agents were originally
developed for the treatment of hypertension and angina, unanticipated side effects
led to advances in the treatment of erectile dysfunction and, later, pulmonary arterial
hypertension. In the last decade, accumulating evidence suggests that PDE5Is may
confer a wider range of clinical benefits than was previously recognised. This has led
to a broader interest in the cardiovascular therapeutic potential of PDE5Is, in condi-
tions such as hypertension, myocardial infarction, stroke, peripheral arterial disease,
chronic kidney disease and diabetes mellitus. Here, we review the pharmacological
properties and established licensed uses of this class of drug, along with emerging
therapeutic developments and possible future indications.
1 | INTRODUCTION
Few other pharmaceutical agents have had a history as serendipitous
as the class of PDE type 5 inhibitors (PDE5Is; Figure 1). Developed
over 30 years ago, initially for cardiovascular indications, PDE5Is
emerged as a revolutionary treatment for erectile dysfunction (ED),
licensed in 1998 (Goldstein, Lue et al., 1998). Further investigation of
their effects on pulmonary arterial pressure culminated in their
approval for the treatment of pulmonary arterial hypertension (PAH)
in 2005 (Galiè, Ghofrani et al., 2005). Early reports of fatal cardiovas-
cular events in patients prescribed a PDE5I delayed wider research
into their therapeutic benefits, but it soon became apparent that these
adverse events reflected the complex nature of patients initially
receiving the drug and their high level of cardiovascular risk, rather
than the properties of the drug itself (Cheitlin, Hutter et al., 1999;
Giuliano, Jackson et al., 2010). With a growing body of evidence
supporting the clinically established safety profile and efficacy of
Abbreviations: 6MWD, 6-min walking distance; ACEI, ACE inhibitor; ARB, angiotensin
receptor blocker; BPS, British Pharmacological Society; CCB, calcium channel blocker; CKD,
chronic kidney disease; Cmax, maximum plasma/serum concentration; CTEPH, chronic
thromboembolic pulmonary hypertension; CVD, cardiovascular disease; CYP2C19,
cytochrome P450, family 2, subfamily C, polypeptide 19; CYP2C9, cytochrome P450, family
2, subfamily C, polypeptide 9; CYP2D6, cytochrome P450, family 2, subfamily D, polypeptide
6; CYP3A, cytochrome P450, family 3, subfamily A; CYP3A4, cytochrome P450, family
3, subfamily A, polypeptide 4; CYP450, cytochrome P450 enzyme family; DN, diabetic
nephropathy; ED, erectile dysfunction; eGFR, estimated GFR; ERA, endothelin receptor
antagonist; ET, endothelin; ET-1, endothelin-1; FGR, fetal growth restriction; GSK3B,
glycogen synthase kinase 3 β; HbA1c, glycated Hb; HFpEF, heart failure with preserved
ejection fraction; HFrEF, heart failure with reduced ejection fraction; IC50, half maximal
inhibitory concentration; IUPHAR, International Union of Basic and Clinical Pharmacology;
MI, myocardial infarction; mitoKATP, mitochondrial ATP-sensitive potassium channels;
NAION, nonarteritic anterior ischaemic optic neuropathy; Na+/K+-ATPase, sodium–
potassium pump; NOS1, neuronal NOS; NOS2, inducible NOS; NOS3, endothelial NOS; PAH,
pulmonary arterial hypertension; PDE5I, PDE type 5 inhibitor; PH, pulmonary hypertension;
PPHN, persistent pulmonary hypertension of the newborn; RCT, randomised controlled trial;
RHTN, treatment-resistant hypertension; RP, Raynaud's phenomenon; sGC, soluble GC;
SGLT2, sodium–glucose cotransporter 2; Tmax, time taken to reach the maximum plasma
concentration; T2DM, type 2 diabetes mellitus; UACR, urinary albumin/creatinine ratio; V/Q,
ventilation/perfusion.
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these agents, PDE5Is became available as over-the-counter pharmacy
medicines in the United Kingdom in early 2018. Now, there is ren-
ewed research interest in their therapeutic potential in conditions
including cardiovascular disease (CVD), chronic kidney disease (CKD)
and diabetes mellitus. This narrative literature review discusses the
historical and biochemical basis for the established uses of PDE5Is
and presents emerging evidence of their utility in novel indications.
2 | METHODS
We conducted a literature search of multiple electronic databases
including Medline, Embase, Cochrane Library, Google Scholar and Trip
medical database over the period of December 2016 to September
2019. Search terms included, but were not limited to, phosphodiester-
ase type 5, phosphodiesterase type 5 inhibitors, erectile dysfunction,
pulmonary hypertension, lower urinary tract symptoms, cardiovascular
disease, blood pressure, stroke, connective tissue disease, chronic kid-
ney disease and diabetes mellitus. One hundred and fifty articles were
included in our qualitative synthesis and are referred to in this review.
3 | BIOCHEMISTRY
Before discussing the current use of PDE5Is and their new clinical
indications, we briefly review the underlying cellular and molecular
processes. Where relevant, endogenous ligands and drugs mentioned
in the text are hyperlinked directly to The International Union of Basic
and Clinical Pharmacology (IUPHAR) /British Pharmacological Society
(BPS) Guide to Pharmacology (https://www.guidetopharmacology.
org), an online, expert-curated database with up-to-date information
on drug targets and the substances that act on them (Harding,
Sharman et al., 2018).
Cyclic nucleotide PDEs are a diverse family of enzymes that regu-
late the cellular levels of the secondary messenger molecules cAMP
and cGMP by catalysing the degradation of their phosphodiester bond
(Boswell-Smith, Spina, & Page, 2006). The superfamily of PDE
enzymes is classified into 11 major isozyme groups, namely, PDE1–
PDE11, each with different substrate specificities: PDE5 together
with PDE6 and PDE9 are selective cGMP hydrolases, whereas other
PDEs are cAMP-selective (PDE4, PDE7 and PDE8) or have mixed
specificity (PDE1, PDE2, PDE3, PDE10 and PDE11; Boswell-Smith,
Spina, & Page, 2006). Although PDE5 is abundantly distributed in vas-
cular smooth muscle, PDE5 mRNA and isoform expression has also
been identified in various human organs, including brain, lung, heart,
liver, kidney, bladder, prostate, urethra, penis, uterus and skeletal
muscle, where it performs numerous physiological functions mediated
by the NO–cGMP pathway (Figure 2; Boswell-Smith, Spina, & Page,
2006). Due to its widespread tissue distribution and functions,
PDE5 has been established as an attractive target for pharmacological
intervention to prolong or enhance the effects of processes
mediated by cGMP by inhibiting its degradation (Boswell-Smith,
Spina, & Page, 2006).
cAMP and cGMP play key roles in cell signalling through the acti-
vation of intracellular protein kinases which modulate several meta-
bolic processes such as ion conductance, cellular apoptosis and
glycogenolysis. In smooth muscle cells, for example, the binding of
cGMP to the cGMP-dependent PKG causes a reduction in intracellu-
lar calcium concentrations and, subsequently, relaxation of the
smooth muscle layer and vasodilatation (Boswell-Smith, Spina, & Page,
F IGURE 1 Milestones in the development of PDE type 5 inhibitors (PDE5Is). The figure depicts the key milestones in the development of
PDE5Is for clinical indications, from their inception and early clinical trials, to their success in the amelioration of several cardiovascular conditions
and finally their availability as an over-the-counter medication. BP, blood pressure; BPH, benign prostatic hyperplasia; DN, diabetic nephropathy;
ED, erectile dysfunction; EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; LUTS, lower urinary tract symptoms; NO,
nitric oxide; PAH, pulmonary arterial hypertension; PDE5I, PDE type 5 inhibitor; RHTN, treatment-resistant hypertension; T2DM, type 2 diabetes
mellitus
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2006). cGMP is synthesised from GTP by soluble GC (sGC), a
heterodimeric enzyme which is itself activated by NO. NO is a cellular
signalling molecule implicated in a wide range of regulatory functions,
including control of vascular tone, platelet aggregation and cell com-
munication, as well as in the immunological response to infection,
chronic inflammation and tumours (Ignarro, 2019). NO is synthesised
endogenously from the oxidation of the amino acid L-arginine to L-
citrulline under the effect of NOS, of which there are three isoforms,
neuronal NOS (NOS1), inducible NOS (NOS2) and endothelial NOS
(NOS3), but can also be derived from the reduction of exogenously
administered nitrates (Stuehr & Haque, 2019).
Vascular smooth muscle relaxation is also mediated by the effects
of the prostacyclin pathway, whereby arachidonic acid is cleaved by
cyclooxygenase to synthesise prostacyclin, a lipid molecule with
potent vasodilatory, anti-proliferative and anti-platelet effects medi-
ated through interactions with cell surface and nuclear receptors,
which ultimately result in increased cAMP production and PKA activa-
tion (Mitchell & Kirkby, 2019). Local vascular tone is regulated by an
interaction between these relaxing processes and the effects of con-
strictor actions, including the endothelin (ET) pathway, primarily medi-
ated by secretion of the potent vasoconstrictor endothelin-1 (ET-1)
from vascular endothelial cells. Cumulative evidence suggests that the
ET pathway opposes the NO–cGMP pathway and contributes to the
pathogenesis of several cardiovascular and inflammatory diseases.
Pharmacological manipulation of this system via inhibition of ET bio-
synthesis or direct antagonism of ET receptors has generated signifi-
cant experimental interest and potential therapeutic applications
(Dhaun & Webb, 2019).
The vasodilatory properties of the NO–cGMP pathway have been
successfully exploited for the management of ischaemic heart disease,
whereby exogenous nitrate administration in the form of nitroglycerin
reduces peripheral vascular resistance and cardiac preload to improve myo-
cardial perfusion. However, despite its potent anti-anginal effect, such
practice is limited by the rapid development of nitrate tolerance with
sustained exogenous administration. In an attempt to circumvent this issue,
research interest in the mid-1980s shifted to the modulation of intracellular
cGMP levels and its downstream effectors (Beavo & Reifsnyder, 1990).
4 | DEVELOPMENT OF PDE TYPE
5 INHIBITORS
In 1986, Pfizer began preclinical work on the development of a selec-
tive PDE5-inhibitor (PDE5I) to compete with cGMP for access to the
PDE5 catalytic site. It was proposed that such an agent could prolong
the effects of NO–cGMP signalling in vascular tissue and thus
F IGURE 2 The NO–cGMP signalling pathway in the vasculature. The figure shows the generator cells, for example, vascular endothelial cells,
the target cells, for example, vascular smooth muscle cells and biochemical processes involved in NO signalling in the vasculature. NO is produced
through the conversion of the substrate L-arginine to L-citrulline by endothelial NO synthase (NOS3) in vascular endothelial cells. Subsequently,
NO diffuses to neighbouring vascular smooth muscle cells where it activates soluble GC (sGC), which converts guanosine triphosphate (GTP) to
cGMP. cGMP is a secondary messenger enacting cellular processes through the regulation of protein-dependent kinases, for example, PKG, and
cGMP-gated ion channels. The cellular actions of cGMP can be prolonged by PDE type 5 inhibitors (PDE5Is), which prevent its degradation by
PDE type 5 (PDE5), resulting in vasodilatory, antioxidative and anti-proliferative effects in several organ systems and diseases. Icons with
permission from ©iStock.com/Alex Doubovitsky
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ameliorate conditions associated with NO deficiency, such as angina
pectoris. In preclinical studies, the resulting agent — later named
sildenafil citrate — demonstrated potent vasodilatory effects and
was selected for further development (Terrett, Bell et al., 1996). In
1991, sildenafil entered clinical trials for use in cardiovascular indica-
tions. In single-dose trials, the agent produced reductions in systemic
BP in healthy volunteers, as well as modest vasodilatory and anti-
platelet effects when administered intravenously to patients with
ischaemic heart disease (Boswell-Smith, Spina, & Page, 2006; Jack-
son, Benjamin et al., 1999). Despite these initial promising results,
research on the cardiovascular benefits of PDE5I therapy was com-
plicated by the short plasma half-life of sildenafil of around 4 hr,
which would necessitate frequent dosing for the chronic treatment
of angina. Development was further compounded by the contraindi-
cation of concurrent nitrate use within 24 hr of PDE5I ingestion
(48 hr for tadalafil) due to the risk of a significant synergistic
vasodilatory interaction between the agents on the systemic vascula-
ture, leading to dangerous levels of hypotension in recipients (Webb,
Freestone et al., 1999).
5 | THERAPEUTIC APPLICATION OF PDE
TYPE 5 INHIBITORS
5.1 | Erectile dysfunction (ED)
As multiple-dose Phase I trials of sildenafil for the treatment of
angina continued, healthy volunteers began reporting an unexpected
and, in hindsight, fortuitous side effect: penile erections. ED,
defined as the inability to attain or maintain a penile erection suffi-
cient for successful vaginal intercourse (Lue, 2000), had, until the
1990s, been a clinically neglected issue, despite its global burden.
At the time, therapeutic options for ED were limited to experimen-
tal intracavernosal injections of prostacyclin analogues or unlicensed
antidepressants and herbal remedies, which had limited effective-
ness and potential harms (Goldstein, Lue et al., 1998). A break-
through in our understanding of this condition came in 1990, when
NO was identified as a key neurotransmitter facilitating penile erec-
tions. Its release into the penile vasculature at high levels from the
endothelium and parasympathetic cavernous nerve terminals during
sexual stimulation led to cGMP-mediated relaxation of corpus
cavernosal smooth muscle with subsequent vasocongestion, occlu-
sion of local venous return, and a sustained erection (Ignarro, Bush
et al., 1990). By 1993, the future of sildenafil as a treatment for
angina looked increasingly uncertain. However, the occurrence of
penile erections, linked with a clear mechanistic underpinning, pro-
vided the stimulus for the first clinical trials of PDE5Is for the treat-
ment of ED.
The results from the first clinical study investigating PDE5I treat-
ment in ED were unequivocally positive: Through the inhibition of
cGMP degradation in the cavernous smooth muscles, sildenafil
enhanced and prolonged the vasodilatory response of cGMP within
the corpora cavernosa during sexual stimulation in a dose-dependent
manner to facilitate penile erection, without any safety concerns
(Boolell, Allen et al., 1996). Later trials would confirm the high
response rates, with the benefits of sildenafil treatment extending to
ED associated with CVD, neurological disease, diabetes mellitus and
radical prostatectomy (Lue, 2000).
In March 1998, sildenafil citrate (Viagra®; Pfizer; New York City,
New York, USA) was approved for use in both the United States and
the European Union as the first-line treatment for ED secondary to a
broad variety of physical causes (Goldstein, Lue et al., 1998; Ignarro,
2019); within 8 months, more than six million prescriptions of sildena-
fil were written in an unparalleled maelstrom of publicity (Lue, 2000).
The testing and approval of other PDE5Is for the treatment of ED
soon followed, culminating in 2003 with U.S. Food and Drug Adminis-
tration and European Medicines Agency approval of tadalafil (Cialis®;
Eli Lilly and Company; Indianapolis, Indiana, USA), the longest acting
PDE5I,and vardenafil (Levitra®; Bayer; West Haven, Connecticut,
USA), the first PDE5I to be available in both film-coated and oro-
dispersible tablet forms to facilitate adherence in difficult patient
groups. This was followed in 2012 by the introduction of avanafil
(Stendra®; Vivus, Incorporated; Mountain View, California, USA), a
more PDE5-selective agent with favourable tolerability. Alternative
PDE5Is have also been licensed in some countries: udenafil is a rapid-
onset but long-acting agent available in South Korea, Russia and the
Philippines (Paick, Kim et al., 2008); mirodenafil is a short-acting
PDE5I which has been extensively studied in ED but is currently only
marketed in South Korea (Paick, Ahn et al., 2008); lodenafil is another
short-acting agent, which is only available in Brazil (Glina, Toscano
et al., 2009). The clinical implications of these pharmacokinetic and
pharmacodynamic variations in PDE5Is are explored further in the
pharmacology and safety section.
5.2 | Pulmonary hypertension
The demonstration of safe, consistent vasodilatation by sildenafil dur-
ing treatment for ED generated renewed interest in the potential
effects of PDE5 inhibition in other vascular beds. Pulmonary hyper-
tension (PH) is a disorder characterised by a progressive increase in
pulmonary vascular resistance resulting in right heart failure. Five sub-
classes of PH have been defined (as per the classification of the 6th
World Symposium on Pulmonary Hypertension Task Force), among
which Group 1 represents PAH, a term which encompasses a number
of heterogeneous conditions sharing common pathophysiological, his-
tological and prognostic features (Simonneau, Montani et al., 2019).
Prior to 2005, treatment options for PAH included prostacyclin and
prostacyclin analogue therapy, and the non-selective ET receptor
antagonist (ERA) bosentan. Although these drugs were successful in
improving prognosis and exercise capacity in individuals with PAH,
they were limited by concerns over safety, tolerability and ease of
delivery (Simonneau, Montani et al., 2019). However, it should be
noted that these issues have since been addressed following the
development of novel ERAs. Both ambrisentan, an ET-A selective
agent, and macitentan, a dual ERA with a long half-life and sustained
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receptor binding, have demonstrated favourable efficacy and tolera-
bility profiles in the treatment of PAH (Galiè, Olschewski et al., 2008;
Pulido, Adzerikho et al., 2013).
Local NO production regulates ventilation/perfusion (V/Q)
matching as its production is up-regulated in response to alveolar dis-
tension, leading to redirection of blood flow to well-ventilated areas
of the lung (Ghofrani, Pepke-Zaba et al., 2004). PDE5 is highly
expressed in healthy lung tissue (Corbin, Beasley et al., 2005) and up-
regulation of PDE5 gene expression was first observed in the lungs of
rats with PH (Sanchez, De La Monte et al., 1998). Moreover, the weak
and relatively non-selective PDE5Is zaprinast and dipyridamole
improved pulmonary pressure in models of PH (Ichinose, Adrie et al.,
1998; Ziegler, Ivy et al., 1998). These factors, combined with the pros-
pect of a well-tolerated oral agent to enhance NO/cGMP-mediated
vasodilatation specifically in areas of poor perfusion through the aug-
mentation of V/Q matching, made PDE5 an ideal target for pharmaco-
logical intervention.
The first placebo-controlled study investigating the effect of
intravenous sildenafil in PH patients showed significant reductions
in pulmonary pressure and pulmonary vascular resistance (Ghofrani,
Osterloh, & Grimminger, 2006). Following several case reports and
clinical trials confirming the anti-pulmonary hypertensive effects of
sildenafil (Ghofrani, Osterloh, & Grimminger, 2006), this growing
body of evidence culminated in the pivotal Sildenafil Use in Pulmo-
nary HypERtension (SUPER-1) study in 2005: a large, multinational,
randomised controlled trial (RCT) which demonstrated improve-
ments in both functional and haemodynamic outcomes from base-
line to week 12 following three times daily sildenafil administration
(Galiè, Ghofrani et al., 2005). In a long-term extension study,
improvements were maintained after 3 years of therapy (Rubin,
Badesch et al., 2011). Oral sildenafil (Revatio®; Pfizer) was approved
for the treatment of PAH in both the United States and the
European Union in 2005, followed by tadalafil (Adcirca®; Eli Lilly
and Company) in 2009.
There have now been several RCTs demonstrating the clear bene-
fits of sildenafil, tadalafil, and vardenafil in PAH, despite a lack of com-
parative therapeutic data between the agents and the fact that
vardenafil is not currently licensed for treatment. A recent Cochrane
systematic review and meta-analysis of 36 studies involving 2,999
patients concluded that patients receiving PDE5Is were more likely to
significantly improve their WHO functional class and 6-min walking
distance (6MWD)—a measure of exercise capacity—and were less
likely to die, despite an increase in the incidence of side effects such
as headache, flushing, and myalgia (Barnes, Brown et al., 2019). Prom-
isingly, these benefits are seen across the PH Group 1 subclass
regardless of PAH aetiology, whether idiopathic or associated with
connective tissue disease, congenital heart disease, or infection with
human immunodeficiency virus (Barnes, Brown et al., 2019). Recently,
the AMBITION study demonstrated the rationale for early interven-
tion and targeting multiple pathways in PAH by showing a significant
mortality benefit in treatment-naïve PAH patients receiving long-term
tadalafil–ambrisentan combination therapy compared to monotherapy
with either agent (Galiè, Barberà et al., 2015). This evidence of
PDE5I–ERA synergy has been adopted in current European guide-
lines, which favour the use of PDE5I or ERA monotherapy for low-risk
patients (WHO functional class I–III), escalating to the use of combina-
tion therapy or intravenous prostacyclin for those at high risk (WHO
functional class IV; Hoeper, McLaughlin et al., 2016).
However, existing evidence is insufficient to establish whether
pulmonary vasodilatory therapies are safe and effective in other PH
subclasses (Hoeper, McLaughlin et al., 2016). Although there is mixed
evidence to support PDE5I therapy in PH secondary to left-heart dis-
ease (Group 2; Hutchings, Anderson et al., 2018), there is no clear
benefit for use of the agents in PH due to lung disease and/or hypoxia
(Group 3) or thrombotic obstruction (Group 4; Barnes, Brown et al.,
2019). Indeed, the results seem conflicting even within the same sub-
class. In PH Group 5 (secondary to systemic or haematological dis-
ease), tadalafil significantly improved haemodynamic parameters in β-
thalassaemia intermedia with PH, whereas a trial of sildenafil in PH
secondary to sickle cell disease was terminated as a result of a signifi-
cant increase in clinical worsening and hospitalisation (Barnes, Brown
et al., 2019). Similarly, PDE5Is may be harmful in valvular heart dis-
ease, a subtype of PH Group 2 (Barnes, Brown et al., 2019). There-
fore, whilst PDE5Is have demonstrated significant disease-modifying
properties in PH Group 1 (PAH), the limited and heterogenous nature
of trials in other PH subclasses prevents conclusive interpretation of
their risk–benefit profile, thus prohibiting their recommendation for
the treatment of PH Groups 2 to 5.
Interestingly, therapeutic NO–cGMP intervention with the sGC
stimulator riociguat has shown promise in the treatment of chronic
thromboembolic PH (CTEPH), the main Group 4 subtype, by reducing
pulmonary artery pressure and improving WHO functional class and
6MWD. Although evidence of mortality benefit is lacking, riociguat is
currently recommended as a first-line therapy in the treatment of
CTEPH patients who are unfit for pulmonary endarterectomy (Barnes,
Brown et al., 2019; Wardle, Seager et al., 2016). Future research into
the therapeutic potential of NO–cGMP intervention in PH Groups
2 to 5 should be sufficiently powered and incorporate long-term
follow-up of clinical, haemodynamic and mortality parameters. This
will be aided by further elucidation of the mechanisms of left-heart
disease PH, borderline mean pulmonary arterial pressure increases
and mixed clinical phenotypes.
6 | EMERGING THERAPEUTIC USES OF
PDE TYPE 5 INHIBITORS
6.1 | Cardiovascular disease
CVD now accounts for one third of global mortality—over 90% of
these deaths are attributable to three conditions: ischaemic heart
disease, stroke and hypertensive heart disease (Joseph, Leong
et al., 2017). Research into the cardiovascular benefits of PDE5Is
was deferred for several years due to early reports of adverse car-
diovascular events in patients prescribed sildenafil (Cheitlin, Hutter
et al., 1999). In hindsight, however, this reflected the nature of the
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patients receiving the drug and long-term evidence has since
established the safety of PDE5Is in both health and CVD (Giuliano,
Jackson et al., 2010). Moreover, the demonstration of PDE5
expression in human heart tissue has renewed interest in the use
of PDE5Is in this field (Pokreisz, Vandenwijngaert et al., 2009).
6.1.1 | Endothelial function
The vascular endothelium, a continuous monolayer of cells lining the
entire cardiovascular system, has a key role in a wide range of physio-
logical processes, including regulation of vascular tone and response
to inflammation. Endothelial functions are partially mediated by NO–
cGMP signalling, deficiency of which is a key feature of endothelial
dysfunction (Napoli & Ignarro, 2009), a pro-thrombotic and pre-
atherosclerotic state which underlies several diseases and is an impor-
tant adverse modifier of CVD risk and clinical outcomes (Brunner,
Cockcroft et al., 2005). As highlighted in a recent review (Schwartz,
Jackson et al., 2013), both single-use and long-term administration of
PDE5Is in patients with high cardiovascular risk have been shown to
ameliorate endothelial function parameters, reduce plasma concentra-
tions of ET-1 and endothelial inflammatory mediators and increase
levels of circulating endothelial progenitor cells. Promisingly, several
studies have indicated that PDE5I-mediated improvements in endo-
thelial function may be sustained for weeks to months after discontin-
uation of long-term treatment (McLaughlin, Lytvyn et al., 2014),
signifying that, in addition to their acute haemodynamic effects, the
agents may produce fundamental modifications at a cellular level,
which may explain the therapeutic effects of PDE5Is in CVD, CKD
and diabetes mellitus, as discussed below. Moreover, limited clinical
data suggest that sildenafil provides sustained pharmacological
preconditioning of human endothelium which may protect against the
adverse effects of ischaemia–reperfusion on vascular function
(McLaughlin, Lytvyn et al., 2014).
6.1.2 | BP homeostasis
Hypertension is the most important global risk factor for CVD (Olsen,
Angell et al., 2016). NO–cGMP signalling is central to the regulation
of BP homeostasis in hypertension through its effects on vascular
tone, the sympathetic nervous system, and renal salt and water han-
dling (Mergia & Stegbauer, 2016). The vasodilatory effects of PDE5Is
provide a rationale for use in systemic arterial hypertension: Acutely,
single doses of PDE5Is result in transient reductions of both periph-
eral and aortic BP, although some variation in effect exists between
health and hypertension and between different PDE5Is (Jackson,
Benjamin et al., 1999; Kloner, Mitchell, & Emmick, 2003; Mahmud,
Hennessy, & Feely, 2001; Pomara, Morelli et al., 2004). In a landmark
study, regular sildenafil monotherapy for 16 days significantly
reduced ambulatory BP by around 6 mmHg in patients with untreated
hypertension compared to placebo (Oliver, Melville, & Webb, 2006).
These results were further supported by the demonstration of
significant ambulatory BP reductions in hypertensive patients of
around 6 mmHg following 28 days of monotherapy with PF-
00489791, a highly specific and long-acting PDE5I, compared to pla-
cebo (Wolk, Smith et al., 2009). In both studies, PDE5I use was safe
and well-tolerated.
Alternative uses for PDE5Is are also being explored in the field
of treatment-resistant hypertension (RHTN). Several studies have
demonstrated the safety of PDE5I use in combination with other
antihypertensive therapies (Kloner, Brown et al., 2001; Kloner,
Mitchell et al., 2003; Nehra, 2009; Pickering, Shepherd et al., 2004).
Concomitant administration of organic nitrates and PDE5Is is cur-
rently contraindicated due to the acute risk of hypotension (Webb,
Freestone et al., 1999), although more recent studies have suggested
that the interaction between the two agents is confined to within
6 hr post-sildenafil administration (Oliver, Kerr, & Webb, 2009; Par-
ker, Bart et al., 2007). Nevertheless, the synergistic hypotensive
interaction occurring with concomitant PDE5I and nitrate adminis-
tration may yet be exploited therapeutically, as demonstrated in a
proof of concept study in which sildenafil and isosorbide
mononitrate combination therapy in RHTN patients produced an
additional BP reduction superior to the two agents individually,
suggesting a novel approach for the treatment of RHTN (Oliver,
Dear, & Webb, 2010). Recently, a crossover trial showed that acute
administration of sildenafil reduced mean BP and improved diastolic
dysfunction parameters in patients with RHTN by facilitating a
reduction in total peripheral resistance (Quinaglia, de Faria et al.,
2013). Notably, exploratory analysis revealed that NOS3 polymor-
phism between subjects may have played a role in modulating the
sildenafil response. PDE5 activation has also been implicated in
angiotensin II-dependent hypertension (Ramseyer, Ortiz et al., 2016)
and in experimental models, PDE5 inhibition has been demonstrated
to reduce angiotensin II levels and restore the baroreflex in renovas-
cular hypertension (Cavalcanti, Alves et al., 2016; Dias, Rodrigues
et al., 2014).
6.1.3 | Cardioprotection
The NO–cGMP signalling pathway has been identified as a survival
signal in ischaemic heart disease (Burley, Ferdinandy, & Baxter,
2007), facilitating its essential cardioprotective effects via PKG-
dependent phosphorylation of ERK and GSK3B, increased genera-
tion of NO by NOS2/3, activation of PKC and opening of
mitochondrial ATP-sensitive potassium channels (mitoKATP), which
stabilise the membrane potential to allow ATP synthesis and calcium
ion transport (Inserte & Garcia-Dorado, 2015). Preclinical studies
have successfully shown that PDE5Is can enhance this pathway in
ischaemia–reperfusion injury and myocardial infarction (MI) by
increasing levels of inducible and NOS3 activity in the heart (Das,
Xi, & Kukreja, 2005), augmenting mitoKATP opening via PKG-
dependent mechanisms (Ockaili, Salloum et al., 2002) and delaying
normalisation of intracellular acidosis (Inserte, Barba et al., 2011).
These effects are independent of vasoactive properties, mediated
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instead through direct myocardial anti-inflammatory and anti-
apoptotic processes (Das, Xi, & Kukreja, 2005; Salloum, Abbate
et al., 2008). These mechanisms of post-ischaemic protection have
been linked to significant reductions in infarct size and car-
diomyocyte death in animals, regardless of the timing of PDE5I
administration, whether given minutes to weeks in advance of the
ischaemic insult (preconditioning; Jamnicki-Abegg, Weihrauch et al.,
2007; Ockaili, Salloum et al., 2002; Salloum, Abbate et al., 2008;
Wang, Fisher et al., 2008), or indeed immediately prior to or during
coronary reperfusion (postconditioning; Ebner, Ebner et al., 2013;
Madhani, Hall et al., 2010; Salloum, Takenoshita et al., 2007). How-
ever, there is no experimental evidence on the administration of
PDE5I during reperfusion following more than half an hour of
ischaemia, which may more accurately reflect clinical practice, asso-
ciated with delayed patient presentation and longer inter-hospital
transfer times.
Similarly, the rationale for PDE5I-mediated augmentation of
the cGMP–PKG pathway in select cases of MI and heart failure
has been fully appraised in a recent review (Hutchings, Anderson
et al., 2018). The authors conclude that PDE5Is may ameliorate
the clinical condition of patients with heart failure with reduced
ejection fraction (HFrEF) through improvements in the pulmonary
circulation, cardiac remodelling and diastolic function. In heart
failure with preserved ejection fraction (HFpEF), however, these
beneficial observations are largely offset by a reduction in
cardiac contractility. Therefore, PDE5I use in heart failure may
be limited to HFrEF and HPpEF with associated PH or right
ventricular systolic impairment, although the underlying signalling
pathways for this variation in effect are not well understood.
In future studies, careful patient stratification by phenotype is cru-
cial. The cardioprotective effects of PDE5Is are also being investi-
gated in chemotherapy-induced cardiotoxicity, where adjunctive
treatment has been shown to reduce apoptosis and improve left
ventricular function without interfering with the chemotherapeutic
benefits of doxorubicin (Fisher, Salloum et al., 2005; Koka, Das
et al., 2010).
6.1.4 | CNS effects
The NO–cGMP signalling pathway is involved also in several physi-
ological and pathological cerebral functions. PDE5 is widely
expressed in the CNS in neural and vascular tissue (Zhang, Zhang, &
Chopp, 2013), and PDE5Is have been shown to cross the blood–
brain barrier to directly affect brain tissue (García-Barroso,
Ricobaraza et al., 2013; Gómez-Vallejo, Ugarte et al., 2016), perhaps
by enhancing angiogenesis and neurogenesis (Zhang, Zhang, &
Chopp, 2013), highlighting the potential for therapeutic intervention
in both ischaemic stroke and neurodegenerative disorders. However,
the few studies investigating these effects in humans are limited by
their focus on cerebral blood flow (Pauls, Moynihan et al., 2018),
which is not a key surrogate for brain function. Moreover, their
findings are inconclusive, and there is no attempt to correlate
changes in blood flow to improvements in cognitive function.
Therefore, the potential relevance of PDE5I therapy to cerebrovas-
cular disease remains uncertain. Nevertheless, recent developments
in our understanding of the neurophysiological roles of NO–cGMP
signalling, reviewed elsewhere (Garthwaite, 2019), may yield novel
interventional opportunities in stroke and other neurological
disorders.
6.1.5 | Peripheral circulation
Reports of improvements in walking distance in patients with both
limb and buttock claudication following sildenafil therapy support the
potential for PDE5I therapy to benefit patients with peripheral arterial
disease (Omarjee, Le Pabic et al., 2019). In a similar fashion to the
angiogenic potential of PDE5Is demonstrated in experimental stroke
models, preclinical studies have demonstrated improvements in vascu-
lar perfusion, tissue blood flow, and vascular density with sildenafil
(Senthilkumar, Smith et al., 2007) and vardenafil (Sahara, Sata et al.,
2010) in a mouse model of unilateral hindlimb ischaemia. Recently, a
prospective crossover study of 12 patients reported a significant
improvement in maximal walking time with a single oral dose of silden-
afil, although this did not impact pain-free walking time or skin tissue
oxygenation during exercise (Omarjee, Le Pabic et al., 2019). Further
prospective studies investigating the impact of PDE5I treatment on
clinical outcomes are ongoing (Table 3).
The vasodilatory and endothelial effects of PDE5Is have also
shown promise in the treatment of Raynaud's phenomenon (RP).
RP is a condition characterised by episodic cold- or stress-induced
ischaemic vasospastic episodes affecting the digital arteries and
arterioles leading to ulcerations and necrosis and is either idiopathic
(primary RP) or due to connective tissue disease (secondary RP). A
recent meta-analysis of six RCTs that included 244 patients with
secondary RP, predominantly due to scleroderma, found that PDE5I
therapy moderately reduced the daily frequency and duration of
vasospastic attacks and promoted visible healing of ulcers (Roustit,
Blaise et al., 2013) and a prospective crossover study suggests that
these beneficial effects also extend to primary RP (Caglayan,
Huntgeburth et al., 2006). These findings suggest that PDE5I ther-
apy may have an equivalent effect on vasospastic attack frequency
to first-line treatment with calcium channel blockers (CCBs) and is
more successful at reducing attack frequency and promoting ulcer
healing than ERAs, an effective and approved treatment for reduc-
ing digital ulceration in scleroderma but which has inconsistent or
minimal effects on other clinical parameters and is of uncertain
benefit in primary RP (Roustit, Blaise et al., 2013). Moreover,
recent interventional trials (Table 3) have demonstrated a signifi-
cant improvement in digital blood flow in patients with secondary
RP following the use of both oral and topical sildenafil preparations
(Andrigueti, Ebbing et al., 2017; Wortsman, Del Barrio-Díaz et al.,
2018), and a recent RCT showed that chronic treatment with sil-
denafil improved healing of digital ulcers secondary to systemic
sclerosis (Hachulla, Hatron et al., 2016).
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Although there has been little research into the therapeutic effi-
cacy of PDE5Is in primary RP, subgroup analysis of a recent RCT
investigating chronic vardenafil use in 53 adults with mixed RP rev-
ealed an increased efficacy in patients with primary RP (Caglayan,
Axmann et al., 2012). However, significant clinical improvement was
not replicated in a series of n-of-1 trials of increasing sildenafil dos-
age in 38 patients with mixed RP (68% of whom had primary RP),
which demonstrated a markedly heterogenous response (Roustit,
Giai et al., 2018). Therefore, although PDE5I therapy may represent
a promising intervention for improving the microcirculation and clini-
cal outcomes of patients with RP, further research with clearer
stratification of RP causality, direct comparison with oral CCBs, and
standardised tools for assessment of digital blood flow is necessary
to clarify the efficacy and safety of these agents and determine
which group of patients may benefit most from treatment.
6.2 | Chronic kidney disease
CKD is a global public health problem characterised by a reduced GFR
and/or evidence of kidney damage (Levin, Stevens et al., 2013). High
BP and diabetes mellitus are major contributors to the development
of CKD and both are associated with an increased risk of CVD. In
addition, CKD is a major independent risk factor for incident CVD,
which remains the main cause of death in these patients (Go, Chertow
et al., 2004). The incidence and prevalence of CKD is rising, and its
progressive clinical course is characterised by high rates of morbidity
and mortality (Hoerger, Simpson et al., 2015).
The past decade has seen substantial progress in understanding
the pathogenesis of CKD, with compelling evidence to suggest that
the NO–cGMP pathway plays an important role in the maintenance
of renal perfusion and glomerular filtration and that CKD is a state of
systemic NO deficiency (Brown, Dhaun et al., 2014). Recently, the
administration of sildenafil in a 5/6 renal ablation model has been
shown to suppress vascular smooth muscle cell proliferation and
inflammation and, subsequently, prevent progression of histological
and functional damage in the remaining glomeruli (Tapia, Sanchez-
Lozada et al., 2012). Moreover, preclinical studies have indicated the
potential for PDE5Is to reverse podocyte dysfunction and normalise
proteinuria, independently of BP (Fang, Radovits et al., 2012; Hall,
Rowell et al., 2014).
Although the first clinical trial to evaluate the potential thera-
peutic benefits of PDE5Is in CKD demonstrated that chronic silden-
afil monotherapy significantly reduced microalbuminuria in patients
with diabetic nephropathy (DN; Grover-Páez, Rivera, & Ortíz,
2007), there were a number of methodological limitations which
prohibited conclusive interpretation of the results (Brown, Dhaun
et al., 2014). In order to address these issues, Pfizer launched an
RCT investigating the use of PF-00489791 for the treatment of
overt DN (Scheele, Diamond et al., 2016). The inclusion criteria dic-
tated a history of at least 3 months of persistent, overt
macroalbuminuria—defined as a urinary albumin/creatinine ratio
(UACR) of over 300 mgg−1 — despite treatment with ACE
inhibitor (ACEI) or angiotensin receptor blocker (ARB) in combina-
tion with antihypertensive and antidiabetic medications. Eligible par-
ticipants had an estimated GFR (eGFR) of 25–59 mlmin−1 per
1.73 m2 (CKD stage G3 or G4) and were randomly assigned to
receive either oral PF-00489791 therapy or placebo once daily for
12 weeks. Remarkably, in the context of treatment-resistant
macroalbuminuria, the PDE5I group demonstrated a significant
reduction in albuminuria as early as the third week of therapy. At
the end of the 12-week treatment period, patients receiving PF-
00489791 had a significant, BP-independent, 16% reduction in
UACR compared with placebo. However, this reduction in UACR
was reversible and was non-significant at 16 weeks, 4 weeks after
the end of treatment. Although there was no difference in eGFR
between treatment and placebo groups throughout the treatment
period, this would be unlikely within the short timeframe. Interest-
ingly, there was no initial short-term fall in eGFR with PDE5I as is
usually observed with ACEI/ARB treatment.
These encouraging results suggest that enhancing NO–cGMP sig-
nalling confers renoprotective effects and improvements in kidney
function, possibly as a result of both haemodynamic and intrarenal
anti-inflammatory, anti-proliferative and antioxidant mechanisms
(Brown et al., 2014). However, no ongoing interventional studies on
the long-term benefits of PDE5I therapy in renal diseases could be
identified (Table 3). We eagerly await the results of two recently com-
pleted studies evaluating the use of PDE5Is in renal disease to deter-
mine whether further research is merited (NCT02414204 and
NCT01960153).
6.3 | Diabetes mellitus
Type 2 diabetes mellitus (T2DM) is characterised by hyperglycaemia
and results from a combination of peripheral insulin resistance and
progressive pancreatic β-cell dysfunction. These pro-inflammatory
states confer higher rates of incident hypertension and cardiovascu-
lar risk. Indeed, CVD accounts for two-thirds of deaths in diabetic
patients, with renal sequelae compounding the high rates of morbid-
ity and mortality of this condition (Wang, Hess et al., 2016). It is
well recognised that achieving tight glycaemic control must be com-
bined with appropriate prevention and management of CVD and
renal disease in order to maximise positive outcomes. Recent data
suggest the potential for PDE5Is to modulate the macrovascular,
microvascular and metabolic complications associated with diabetes
mellitus.
6.3.1 | Macrovascular effects
In a landmark study, a population of 5,956 men diagnosed with
T2DM were monitored over a median period of 7 years to deter-
mine the effect of PDE5I use on their overall survival (Anderson,
Hutchings et al., 2016). Compared to a random sample of non-
users from the same background population, men prescribed a
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PDE5I had a significant 31% lower risk of all-cause mortality. This
reduction in mortality remained statistically significant after
adjusting for known risk modifiers including age, eGFR, smoking
status, prior history of CVD or hypertension, known MI, systolic
BP, lipid profile, number of prescriptions and Townsend deprivation
index, as well as use of cardioprotective agents such as statins,
metformin, aspirin and ß-adrenoceptor antagonists (beta-blockers),
although life course socio-economic position, compliance and doc-
tor selection practices could not be adjusted for. Significant reduc-
tions were also observed in age-adjusted incidence and mortality
rates of acute MI in patients with a history of PDE5I use when
compared to subjects never prescribed this class of drug. Notably,
ED—the most common indication for PDE5I use—is a strong pre-
dictor of subsequent ischaemic heart disease (Gazzaruso, Solerte
et al., 2008), suggesting that the potential protective effects of
PDE5Is on cardiac tissue and vasculature may offset the pre-
existing additional CVD risk associated with this condition. More-
over, in an RCT of 59 T2DM men with diabetic cardiomyopathy,
3 months of sildenafil treatment led to significant improvements in
cardiac indices compared to placebo (Giannetta, Isidori et al., 2012).
Notably, these men were also on optimal anti-hyperglycaemic,
ACEI/ARB, ß-adrenoceptor antagonists and CCB therapies,
highlighting the additional therapeutic potential of PDE5Is in the
management of diabetic complications.
Although these are promising findings, the exact mechanism by
which PDE5Is may improve survival in diabetic patients is unclear but
may pertain to the ability of PDE5Is to ameliorate, or prevent the
development of, cardiovascular and renal pathology in both diabetic
and non-diabetic subjects.
6.3.2 | Microvascular effects
The cardioprotective effects of PDE5Is may also extend to the dia-
betic myocardium. T2DM is associated with higher levels of inflam-
mation and oxidative stress in the heart, leading to myocardial
injury and worse outcomes compared to healthy heart tissue (Ray,
Cannon et al., 2007). Also, the diabetic myocardium is more sus-
ceptible to ischaemia–reperfusion injury and is resistant to several
cardioprotective modalities (Miki, Itoh et al., 2012). With this back-
ground, it is promising that, in T2DM mice exposed to ischaemia–
reperfusion events, chronic tadalafil treatment significantly reduced
infarct size, improved glucose metabolism, and ameliorated
inflammatory and oxidative profiles in the diabetic myocardium
(Koka, Das et al., 2013; Koka, Xi, & Kukreja, 2012; Varma, Das
et al., 2012). Moreover, an RCT of 54 male patients with T2DM
recently demonstrated significant, sustained improvements in
endothelial parameters following chronic vardenafil use (Santi,
Granata et al., 2016). Interestingly, this was also accompanied by
restoration of testosterone levels in men with hypogonadism as
early as 1 week into the treatment protocol, unrelated to erectile
function scoring and, therefore, possibly independent of sexual
activity.
6.3.3 | Metabolic effects
Clinical trials have suggested that PDE5Is may influence glucose
metabolism. In addition to the reductions in albuminuria seen in stud-
ies evaluating the renoprotective effects of these agents, daily PDE5I
therapy for 1–4 months produced significant decreases in mean gly-
cated Hb (HbA1c) of 0.3–0.59% from baseline (Grover-Páez, Rivera
et al., 2007; Scheele, Diamond et al., 2016), representing a reduction
of hyperglycaemia comparable to that observed with established oral
antidiabetic agents administered for longer treatment periods
(0.5–1.25%; Sherifali, Nerenberg et al., 2010). Given the linear associ-
ation between HbA1c and macrovascular disease, with an estimated
11–16% increase in cardiovascular events for every 11 mmolmol−1
(1%) rise in HbA1c (Wang, Hess et al., 2016), these findings may have
important implications for the management of insulin resistance in
diabetes and obesity.
Insulin has recognised vasodilatory properties mediated by the
up-regulation of NOS3 expression and activity (Kuboki, Jiang et al.,
2000). Insulin resistance has been shown to inhibit this pathway by
reducing endothelial NO bioavailability (Wang, Hess et al., 2016).
This disruption of NO–cGMP signalling and the resulting endothelial
dysfunction has been shown to precede the development of inflam-
mation and insulin resistance across muscle, liver and adipose tissue
in mice with diet-induced obesity (Kim, Pham et al., 2008; Rizzo,
Maloney et al., 2010; Tateya, Rizzo et al., 2011). PDE5Is have
proven anti-inflammatory effects in diabetes-induced endothelial
dysfunction (Schwartz, Jackson et al., 2013) and recent evidence
suggests that PDE5Is have additional direct effects on glucose
metabolism: Significant improvements in insulin sensitivity and glu-
cose uptake have been demonstrated in the muscles of mice fed a
high-fat diet following 12-week sildenafil treatment, suggesting that
PDE5I therapy may improve energy balance and prevent insulin
resistance (Ayala, Bracy et al., 2007). Similar improvements in glu-
cose uptake with PDE5I use have also been reported in experimen-
tal animal (Sabatini, Sgrò et al., 2011; Zhang et al., 2010) and human
(Jansson, Murdolo et al., 2010) studies, further suggesting a link
between NO–cGMP signalling and insulin action. Although insulin
treatment does not induce NO production in insulin resistance (Salt,
Morrow et al., 2003), chronic sildenafil treatment has been shown to
enhance NOS3 activity in insulin resistance conditions (Mammi,
Pastore et al., 2011), suggesting potential for sildenafil to improve
vascular function in diabetes mellitus. Finally, others have demon-
strated that sildenafil may promote adipogenesis via PKG-mediated
up-regulation of lipid accumulation and insulin sensitivity in adipo-
cytes (Zhang, Ji et al., 2010). Indeed, two RCTs have recently
reported an improvement in oral disposition index (a composite mea-
sure of insulin sensitivity and secretion) in patients with the meta-
bolic syndrome following long-term PDE5I therapy, reflecting an
overall improvement in β-cell function (Ramirez, Nian et al., 2015;
Santi, Granata et al., 2016).
Therefore, PDE5I treatment may affect outcomes in patients
with diabetes mellitus through reversal of both vascular dysfunc-
tion, which is associated with increased CVD risk, and metabolic
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impairment. Collectively, the available data provide a strong ratio-
nale for further research into the therapeutic targeting of the NO–
cGMP pathway for the management of T2DM and obesity,
although the promise shown in recent studies with ERAs (Dhaun &
Webb, 2019) and sodium–glucose cotransporter 2 (SGLT2)
inhibitors (Perkovic, Jardine et al., 2019) in patients with T2DM and
renal disease serves to make this a competitive field, to the benefit
of future patients.
7 | PHARMACOLOGY AND SAFETY
PROFILE OF PDE TYPE 5 INHIBITORS
Although all PDE5Is employ the same mechanism of action and exhibit
similar therapeutic efficacy and safety (Jannini, Isidori et al., 2009),
they are distinguished on the basis of their pharmacokinetic and
pharmacodynamic properties (Hatzimouratidis & Hatzichristou, 2005).
7.1 | Pharmacokinetics
The primary pharmacokinetic variables which determine PDE5I
administration are bioavailability, maximum plasma concentration
after an oral dose (Cmax), time to achieve maximum plasma concentra-
tion (Tmax) and terminal half-life (t½; Table 1). All marketed PDE5Is
have a high volume of distribution into the vascular space, tissues and
binding by extravascular proteins such as albumin (Mehrotra, Gupta
et al., 2007). Although comparative bioavailability data between the
agents are lacking, this can be estimated by quantifying the area under
the plasma drug concentration-time curve (AUC). Notably, vardenafil
has a significantly lower AUC than sildenafil and tadalafil, which may
explain its comparatively lower Cmax. However, it is not possible to
correlate these kinetics with the clinical dosing regimens of the other
agents from the information that is publicly available.
Sildenafil, udenafil, vardenafil and avanafil have similar Tmax values
and thus comparable onset of action after oral administration

































Avanafil 200 0.75 5.1 2,920 8,490 484 C23H26CIN7O3 5.2 Highly selective
for PDE5.
Udenafil 200 0.76 9.88 1,137 7,898 517 C25H36N6O4S 8.25 Comparable to
sildenafil for
PDE5.
Mirodenafil 100 1.4 2.5 2,989 7,907 532 C26H37N5O5S 0.33 Comparable to
sildenafil for
PDE5.
Lodenafil 160 1.2 2.4 157 530 1,035 C47H62N12O11S2 0.015 Low activity
against PDE1
and PDE6.
PF-00489791 20 1.1–3.5 11.9–15.7 1,570–1,630 N/A 477 C20H28N8O4S 0.71 Highly selective
for PDE5.
Note. Data sourced from Clerin, Gale, & Tamimi (2014) and Hatzimouratidis, Salonia et al. (2016).
Abbreviations: AUC, area under the plasma drug concentration-time curve; Cmax, maximum plasma serum concentration; FCT, film-coated tablet; IC50, half
maximal inhibitory concentration; MF, molecular formula; PDE5I, PDE type 5 inhibitor; t½, terminal plasma half-life; Tmax, time taken to reach the maximum
plasma concentration.
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(30–60 min), with the latter two having the fastest onset: Vardenafil,
in both formulations, acts within 30 min of intake whereas avanafil is
the only PDE5I approved for use 15–30 min before sexual intercourse
in the treatment of ED. In comparison, mirodenafil and lodenafil have
slightly higher Tmax values, with limited published data suggesting that
these have a similar onset of action to sildenafil, whereas tadalafil has
the highest Tmax, reaching peak plasma concentration after
30–120 min (Hatzimouratidis, Salonia et al., 2016).
Tadalafil and udenafil have the highest t½ of marketed PDE5Is,
although it is unclear whether this is due to either delayed absorp-
tion or degradation. Clinically, this translates to a longer duration
of therapeutic effect (up to 36 hr for tadalafil and 12 hr for
udenafil). Tadalafil is uniquely unaffected by dietary intake, enabling
once daily dosing such as that required for the management of
lower urinary tract symptoms in benign prostatic hyperplasia—an
indication for which tadalafil was licensed in 2011 and which is
further explored in a recent review (Andersson, 2018). Avanafil has
the shortest duration of action (up to 6 hr), with sildenafil,
vardenafil, mirodenafil and lodenafil lasting slightly longer (up to
10–12 hr; Hatzimouratidis, Salonia et al., 2016).
PDE5Is are rapidly metabolised by the cytochrome P450
enzyme family (CYP450) in the liver, chiefly through the CYP3A
system with contributions from CYP2C9, CYP2C19, and CYP2D6
pathways (Mehrotra, Gupta et al., 2007), and systemic clearance of
sildenafil and vardenafil, but not tadalafil, is reduced by mild and
moderate hepatic impairment (Muirhead, Wilner et al., 2002). Both
sildenafil and vardenafil have active metabolites which significantly
contribute to their pharmacological activity (Mehrotra, Gupta et al.,
2007). Although PDE5Is are largely faecally excreted, undergoing
minimal renal clearance due to their extensive tubular reabsorption,
the secondary effects of renal impairment may affect the clearance
of sildenafil through alterations in protein binding or inflammatory
protein synthesis (Muirhead, Wilner et al., 2002). Therefore, patients
with severe hepatic or renal impairment should be prescribed a
lower starting dose of PDE5Is and titrated up as appropriate.
7.2 | Pharmacodynamics
The available PDE5Is differ in their affinity and selectivity for the
PDE5 isoform, with consequent effects on their tolerability and
safety profile. The biochemical affinity of the various agents is
quantified by the half maximal inhibitory concentration (IC50), which
represents the concentration of the agent that is required to inhibit
50% of PDE5 activity in vitro. Affinity is an inverse measure of
potency, such that an agent with a higher IC50 requires a lower
dose to reach therapeutic effect. Selectivity refers to the ability of
a PDE5I to preferentially bind PDE5 over other PDEs (Table 1).
The cross-reactivity of PDE5Is has important implications for the
tolerability of the agent as the ubiquitous presence of PDEs in the
body means that non-selective inhibition may result in wide-ranging
systemic effects.
All agents are generally well-tolerated (Table 2) and share simi-
lar transient, mild side effects, such as facial flushing, headache,
dyspepsia, nasal congestion and dizziness. Tadalafil has also been
associated with myalgia and back pain in up to 6% of patients.
However, sildenafil and, to a lesser extent, vardenafil have demon-
strated cross-reactivity with PDE1 and PDE6. PDE6 is highly
expressed in retinal photoreceptors, where its inhibition causes
transient blue/green colour vision disturbances which coincide with
peak plasma sildenafil concentrations (Hatzimouratidis &
Hatzichristou, 2005). PDE5Is also show some cross-reactivity with
PDE1. PDE1 is highly expressed in vascular smooth muscle, where
its inhibition results in vasodilatation and BP reduction, as demon-
strated recently in rats with novel PDE1-inhibitors (Laursen, Beck
et al., 2017). It has been suggested that the higher incidence of
facial flushing following sildenafil and vardenafil administration,
compared with tadalafil and avanafil, may be the result of greater
PDE1 cross-reactivity (Kouvelas, Goulas et al., 2009). Finally,
tadalafil has been shown to inhibit the activity of PDE11, an iso-
zyme which is expressed in the mammalian testes and prostate,
although no impact on reproductive function has been reported
TABLE 2 Reported PDE5I side effect incidence
PDE5I














Sildenafil 19 14 9 5 0 0 6 0 0 0
Tadalafil 21 5 17 5 9 7 0 0 0 0
Vardenafil 16 12 4 10 0 0 <2 0 0 0
Avanafil 7–8 3–5 2 2 <2 0 0 0 0 0
Udenafil 2–9 11–23 0 4–7 0 0 0 4–7 0–5 0
Mirodenafil 8–11 10–16 3 0 0 0 0 3–4 0–3 0
Lodenafil 15–22 5–6 5–22 5–11 0 0 5–6 0 0 0
PF-00489791 5–21 0 3–15 0 0–12 0 0 0 0 1–9
Note. Data sourced from Glina, Toscano et al. (2009); Hatzimouratidis and Hatzichristou (2005); Limin, Johnsen, & Hellstrom (2010); Paick, Ahn et al.
(2008); Paick, Kim et al. (2008); Scheele et al. (2016); Wang, Burnett et al. (2012); and Wolk, Smith et al. (2009).
Abbreviation: PDE5I, PDE type 5 inhibitor.
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TABLE 3 Ongoing interventional clinical trials of PDE5Is beyond ED and PH
Drug(s) tested Sponsor Target group
Stage of development
(status; clinical identifier)
Results of clinical trial/reason
for termination
Hypertension
Sildenafil University of Edinburgh, UK;
Pfizer, USA




placebo (Oliver, Melville, &
Webb, 2006).




placebo (Wolk, Smith et al.,
2009).
Sildenafil University of Campinas,
Brazil
RHTN Not applicable (completed
2012; NCT01392638)
Significant improvement in
diastolic function and BP
compared to placebo
(Quinaglia, de Faria et al.,
2013).








to placebo. No significant
change in BP (Santos, de
Faria et al., 2014).
Cardiac




HFrEF Phase III (terminated 2015;
NCT01910389)
Terminated by funding agency.
Udenafil Seoul National University
Hospital; Dong-A Pharm,
South Korea
HFrEF Phase III (terminated 2014;
NCT01646515)
Substantial benefit was




HFrEF Phase III (completed 2006;
NCT00309790)
Improved cardiac indices
(Malhotra, Dhakal et al.,
2016).
Sildenafil University of Milan, Italy HFpEF Phase II/III (completed 2009;
NCT00781508 and
NCT01156636)
Improved cardiac indices and
clinical status (Guazzi,
Vicenzi et al., 2011).
Sildenafil University of Milan, Italy HFrEF Phase II (completed 2010;
NCT01185925)
Not reported.
Vardenafil McGuire Research Institute,
USA
IRI after cardiac surgery Phase I (completed 2011;
NCT01260285)
Not reported.
Sildenafil Duke University; NHLBI;
Pfizer, USA
HFpEF Phase III (completed 2012;
NCT00763867)
No effect on exercise capacity
or clinical status (Redfield,
Chen et al., 2013).
Sildenafil Rigshospitalet, Denmark HFpEF after MI Phase IV (completed 2012;
NCT01046838)
No improvement in filling
pressure. Significant
improvements in cardiac
indices, exercise capacity and
diastolic BP (Andersen,
Ersbøll et al., 2013).
Udenafil Seoul National University
Hospital; Dong-A Pharm,
South Korea
HFpEF Phase III (completed 2013;
NCT01599117)
Not reported.
Sildenafil Hospital Ana Nery, Brazil Unspecified HF Phase II/III (completed 2013;
NCT01936350)
No effect on cardiac indices




Mayo Clinic; NCRR; NHLBI,
USA
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TABLE 3 (Continued)
Drug(s) tested Sponsor Target group
Stage of development
(status; clinical identifier)





Sildenafil University Medical Center
Groningen, Netherlands;
Pfizer, USA
HFpEF Phase III (completed 2014;
NCT01726049)
No effect on cardiac indices or
clinical status (Liu, Hummel
et al., 2017).




Udenafil Mezzion Pharma Co. Ltd,






Sildenafil University of Calgary,
Canada; Pfizer, USA




PF-03049423 Pfizer, USA Acute ischaemic stroke Phase II (terminated 2016;
NCT01208233)
Interim analysis demonstrated
futility. No reported safety
concerns (Di Cesare,
Mancuso et al., 2016).
Sildenafil University of Utah, USA Subacute ischaemic
stroke
Phase I (terminated 2017;
NCT02628847)
Recruitment failure.
Sildenafil Henry Ford Hospital, USA Subacute ischaemic
stroke
Phase I (terminated 2011;
NCT00452582)
Recruitment failure.
Tadalafil Herlev Hospital, Denmark Cerebral small vessel
disease
Phase II (completed 2017;
NCT02801032)
Not reported.






Vardenafil University of Cologne,
Germany
Mixed RP Phase II/III (completed 2010;
NCT01291199)
Significant improvement in













clinical symptoms, quality of
life, digital ulcer frequency,
and healing with add-on
PDE5I therapy compared to
placebo (Shenoy, Kumar et
al., 2010).




Udenafil Seoul National University
Hospital, South Korea
Secondary RP Phase II/III (completed 2011;
NCT01280266)
Significant improvement in
digital blood flow compared
to amlodipine. Similar
efficacy in reducing RP
attacks (Lee, Park et al.,
2013).
Sildenafil Lille University Hospital,
France
Secondary RP Phase III (completed 2013;
NCT01295736)
Frequent sildenafil use for
12 weeks significantly
improved healing of digital
ulcers secondary to systemic
sclerosis compared to
placebo (Hachulla, Hatron et
al., 2016).
(Continues)
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TABLE 3 (Continued)
Drug(s) tested Sponsor Target group
Stage of development
(status; clinical identifier)
Results of clinical trial/reason
for termination
Tadalafil Northwestern University; Eli
Lilly and Company, USA
Secondary RP Not applicable (completed
2014; NCT00822354)
Not reported.
Sildenafil Federal University of S~ao
Paulo, Brazil
Secondary RP Phase III (completed 2016;
NCT01347008)
Significant improvement in
digital blood flow and











compared to placebo, with
substantial heterogeneity in
patient response (Roustit,
Giai et al., 2018).
Sildenafil (topical) Pontifical Catholic University
of Chile, Chile
Secondary RP Phase I (completed 2016;
NCT03027674)
Significant improvement in
digital blood flow compared
to topical nifedipine cream
(Wortsman, Del Barrio-Díaz
et al., 2018).
Sildenafil Angers University Hospital,
France
PAD Phase III (completed 2017;
NCT02832570)
Significant improvement in
maximal walking time but no
significant effects on
pain-free walking time and
oxygenation parameters
(Omarjee, Le Pabic et al.,
2019).
Sildenafil Angers University Hospital,
France
PAD Phase II/III (not yet
recruiting; NCT02387450)
Not yet recruiting.
Sildenafil Rennes University Hospital,
France





Sildenafil University of Guadalajara,
Mexico
Diabetic nephropathy Not applicable. Significant reduction in
microalbuminuria compared
to placebo (Grover-Páez,
Rivera et al., 2007).





Diamond et al., 2016).
Mirodenafil Asan Medical Center; SK
Chemicals, South Korea
CKD Phase I (completed 2011;
NCT01232010)
Not reported.



















Hyperglycaemia Phase I (terminated 2015;
NCT01238224)
Durability of study medications
could not be guaranteed
after the expiry date.
(Continues)
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with PDE5I use (Hatzimouratidis & Hatzichristou, 2005). Indeed, a
large meta-analysis suggests that chronic PDE5I use may have a
beneficial effect on spermatogenesis, although the improvements
with tadalafil are less than would be expected given its long
duration of action (Tan, Liu et al., 2017). Although quantitative iso-
zyme affinity and selectivity data for udenafil, mirodenafil and
lodenafil are not publicly available, these are said to have a
comparable selectivity profile to sildenafil, which may explain their
similar side effect profile. In comparison, avanafil and PF-00489791
are newer agents with improved PDE5 selectivity and seemingly
favourable tolerability (Table 2), particularly with respect to visual
disturbances (Wang, Burnett et al., 2012).
In theory, agents with improved PDE5 selectivity may achieve
comparable efficacy with minimal systemic consequences by
TABLE 3 (Continued)
Drug(s) tested Sponsor Target group
Stage of development
(status; clinical identifier)
Results of clinical trial/reason
for termination




Phase IV (completed 2009;
NCT00692237)
Significant improvement in
cardiac kinetic and metabolic
indices compared to placebo









Metabolic syndrome Phase III (completed 2013;
NCT01444651)




compensation (Ho, Arora et
al., 2014).










(Santi, Granata et al., 2016).
Tadalafil University of Roma La
Sapienza, Italy
Metabolic syndrome Phase IV (completed 2015;
NCT02554045)
Not reported.
Tadalafil University of Guadalajara,
Mexico
Metabolic syndrome Phase IV (completed 2015;
NCT02595684)
Not reported.






albuminuria after 3 months
of PDE5I therapy. Sub-study
investigating insulin
signalling in skeletal muscle
not yet reported (Ramirez,
Nian et al., 2015).
Sildenafil + leucine
± metformin
NuSirt Biopharma, USA Metabolic syndrome Phase II (completed 2018;
NCT03364335)
Not reported.














Tadalafil University Center for Health
Science, Mexico
Metabolic syndrome Phase III (ongoing;
NCT03905018)
Ongoing.
Note. Mode of drug administration is oral unless otherwise specified.
Abbreviations: AKI, acute kidney injury; CKD, chronic kidney disease; ED, erectile dysfunction; HF, heart failure; HFpEF, heart failure with preserved
ejection fraction; HFrEF, heart failure with reduced ejection fraction; IRI, ischaemia reperfusion injury; MI, myocardial infarction; NCRR, National Center
for Research Resources; NHLBI, National Heart, Lung, and Blood Institute; PAD, peripheral arterial disease; PDE5I, PDE type 5 inhibitor; PH, pulmonary
hypertension; RHF, right heart failure; RHTN, treatment-resistant hypertension; RP, Raynaud's phenomenon; T2DM, type 2 diabetes mellitus.
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limiting PDE1/PDE6 cross-reactivity. However, the highly selective
agents PF-00489791 and PF-03049423 have recently been with-
drawn from several clinical trials investigating their use in various
cardiovascular indications (https://adisinsight.springer.com/drugs/
800025495), despite a lack of safety concerns and the former's
previously discussed efficacy in hypertension and CKD. Although
PF-03049423 was not found to be effective in improving
outcomes following ischaemic stroke (Di Cesare, Mancuso et al.,
2016), the rationale behind the withdrawal of PF-00489791 is not
publicly available. Similarly, research into KD027/SLx-2101, a
PDE5I which was uniquely converted into a long-acting active
metabolite and had been in the final stages of development for the
treatment of hypertension (NCT00562549 and NCT00562614;
Hatzimouratidis & Hatzichristou, 2008), has also been suspended
following the closure of its sponsor company (Professor
I. Wilkinson, personal communication, September 16, 2019). In
combination with the recent surge in registered trials of sildenafil
and tadalafil in several cardiovascular conditions (Table 3), these
developments indicate a market shift towards re-purposing already
established PDE5Is. Although the reasons for this are unclear, it is
possible that these novel PDE5Is may not have achieved adequate
therapeutic efficacy for their development to be financially
sustainable given recent advancements in the field of cardiovascular
therapeutics, particularly with regard to the extensive and evolving
therapeutic profile of SGLT2-inhibitors.
7.3 | Drug interactions
Although concomitant use of PDE5Is with nitrates, sGC stimulators
and α-adrenoreceptor antagonists is contraindicated due to the risk
of a potent hypotensive interaction (Webb, Freestone et al., 1999),
PDE5Is do not have synergistic effects on BP with other
antihypertensive agents, such as ACEIs, ARBs, beta-blockers, CCBs,
or thiazide diuretics (Kloner, Mitchell et al., 2003; Webb, Freestone
et al., 1999).
Potent inhibitors of the CYP450 system (particularly CYP3A4),
including several antiretroviral protease inhibitors, have been shown
to modify the pharmacokinetics of PDE5Is. Whilst coadministration
has not been associated with changes in the safety or tolerability
of either agent (Muirhead, Wulff et al., 2000), cautious use of a
lower PDE5I dose is still recommended for patients receiving
agents with CYP450 inhibitory properties (Baxter & Preston, 2019).
Lastly, following several years of uncertainty as to whether
PDE5Is were associated with changes in cardiac repolarisation, a
well-designed study in healthy males demonstrated that the small
increases in corrected QT interval which may be observed at higher
doses of the agents are clinically insignificant (Morganroth, Ilson
et al., 2004). In fact, an increasing body of experimental evidence
suggests that PDE5Is may exert antiarrhythmic effects on ischaemic
myocardium through the modulation of voltage-gated calcium
channels, Na+/K+-ATPases and β-adrenoceptor signalling
(Hutchings, Anderson et al., 2018).
7.4 | Nonarteritic anterior ischaemic optic
neuropathy
There is still some uncertainty surrounding the safety profile of
PDE5Is. In particular, there have been numerous case reports and
case series of nonarteritic anterior ischaemic optic neuropathy
(NAION) following use of the agents. NAION, an optic neuropathy
precipitated by a decrease in perfusion pressure in the prelaminar
region of the optic nerve causing ischaemic infarction and sudden,
painless vision loss, is a rare condition, but the leading acquired optic
neuropathy in adults over 50 years old, with an annual incidence of
2–10 cases per 100,000 in this population. Several experimental and
epidemiological studies have failed to establish a definitive effect of
PDE5Is on the ocular circulation or on the risk of NAION (Pomeranz,
2016), which is more likely in the presence of cardiovascular risk fac-
tors such as ED. However, important insights into this association
have recently been provided by two prospective trials using a case–
crossover study design, which controls for the effects of recall bias
and participant characteristics by defining the day of NAION onset
and the day before as the risk period and matching this with control
periods in the preceding weeks. The first, a study of 64 definite or
probable cases of NAION, found a twofold increase in the risk of
NAION within five half-lives of PDE5I use, extending to 2 days after
sildenafil or vardenafil use and 5 days after tadalafil use (Campbell,
Walker et al., 2015). These results were echoed by a second crossover
trial which identified 279 men with confirmed NAION and revealed
that intermittent exposure to a PDE5I within the preceding month
also increased the baseline risk of developing NAION twofold
(Flahavan, Li et al., 2017). These findings translate to an annual contri-
bution of approximately three additional NAION cases per 100,000
men 50 years and older with weekly PDE5I use. Consequently,
PDE5Is are contraindicated in patients with previous NAION or with a
hereditary eye disease.
7.5 | Persistent pulmonary hypertension of the
newborn
Concerns have been raised about the safety profile of PDE5Is in
the treatment of fetal growth restriction (FGR). Despite generally
promising results in preclinical studies and small clinical trials, in
July 2018, the Dutch arm of the international Sildenafil TheRapy In
Dismal prognosis Early-onset fetal growth Restriction (STRIDER)
series of RCTs was prematurely terminated after interim data
suggested an increased risk of persistent pulmonary hypertension
of the newborn (PPHN) and neonatal mortality in the intervention
group (Groom, Ganzevoort et al., 2018). In the sildenafil group,
17 cases of PPHN were recorded in 64 babies (27%) compared to
three of 58 babies (5%) in the placebo group, in the absence of
any survival benefit. In the United Kingdom and the New Zealand
and Australia STRIDER trials, there was no observable difference in
clinically relevant pathological or histological findings between the
sildenafil and placebo groups and no significant amelioration of
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neonatal survival until term age (Sharp, Cornforth et al., 2019).
Although the planned meta-analysis of individual patient data from
these trials is eagerly anticipated, it is uncertain whether PDE5Is
will have a therapeutic role in pregnancies complicated by FGR.
8 | CONCLUSIONS
The proven clinical efficacy and excellent safety profile of PDE5Is
in the management of ED and PAH has led to their introduction as
over-the-counter medications as well as prompting significant
research interest in the use of these agents for the enhancement
of the actions of cGMP in a range of vascular and non-vascular
conditions. In addition to their acute haemodynamic effects, PDE5Is
have demonstrated potent anti-inflammatory, antioxidant, anti-
proliferative and metabolic properties, largely attributable to modu-
lation of the NO–cGMP signalling pathway. A wide array of experi-
mental data suggests a protective effect of PDE5Is in several major
organ systems and therapeutic potential in hypertension, chronic
kidney disease and diabetes mellitus. In particular, the recent asso-
ciation of long-term PDE5I treatment with a reduction in all-cause
mortality merits a broader evaluation of PDE5Is. Ultimately, esta-
blishing the optimal use and long-term safety of these agents in
CVD will depend on the implementation of larger RCTs, particularly
with other comparative treatments, which may be facilitated by the
development of novel, longer acting, and more selective PDE5Is.
8.1 | Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to
corresponding entries in http://www.guidetopharmacology.org, the
common portal for data from the IUPHAR/BPS Guide to
PHARMACOLOGY (Harding et al., 2018), and are permanently
archived in the Concise Guide to PHARMACOLOGY 2019/20
(Alexander, et al.,2019 2019).
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